抗凝对非小细胞肺癌治疗的机制研究

Mechanism of anticoagulation therapy for non-small cell lung cancer

近年来越来越多的研究开始关注恶性肿瘤患者并发的凝血功能异常,不仅导致血栓形成,还与肿瘤的生长、浸润侵袭、转移等密切相关,从而直接影响预后。肝素作为传统抗凝剂已众所周知,且抗凝药物已出现在恶性肿瘤治疗指南中。美国临床肿瘤学会(ASCO)、欧洲肿瘤内科学会(ESMO)以及美国临床药学学会(ACCP)等机构推荐低分子肝素作为治疗癌症相关血栓的首选,然而预防性应用抗凝药物对控制恶性肿瘤、延长PFS及OS的机制仍不明确。本文将从多方面介绍抗凝药物对控制恶性肿瘤的复发转移及延长生存的病理生理学机制。

In recent years, a number of studies have focused on malignant tumor patients with coagulant function abnormality, which causes thrombus complications, tumor growth, infiltration of closely related cells, transfer, and so on. These factors directly affect prognosis. Heparin is a widely known anticoagulant, and anticoagulation drugs have been included in malignant tumor treatment guidelines. Ameaican Society of Clinical Oncology（ASCO）, European Society for Medical Oncology（ESMO）, and American College of Clinical Pharmacy（ACCP） recommend low-molecular-weight heparin as the first choice for the treatment of cancer thrombosis. However, the prophylactic use of anticoagulant drugs in patients with tumor control disease, as well as the prolonged PFS and OS mechanism, is still unclear. The recently published ＂Report of incidence and mortality in China＂（2012） suggests that lung cancer incidence and mortality ranked first place. This review will introduce several aspects of anticoagulant drugs that can be used to control the recurrence of malignant tumor metastasis and prolong the survival mechanism of pathophysiology.